Skip to content
OpenCapital
Get started

Exelixis EXEL Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis?
Exelixis (EXEL) reported cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis of $1.43B in Q1 2026.
How has Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis changed year-over-year?
Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis decreased by 13.4% year-over-year, from $1.65B to $1.43B.
What is the long-term trend for Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis?
Over 5 years (2020 to 2025), Exelixis's cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost basis has grown at a 1.6% compound annual growth rate (CAGR), from $1.53B to $1.66B.